Literature DB >> 33610781

South American Hemorrhagic Fevers: A summary for clinicians.

Maria G Frank1, Adam Beitscher2, Camille M Webb3, Vanessa Raabe4.   

Abstract

OBJECTIVES: This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which there are no or limited licensed medical countermeasures. We approached this summary on South American Hemorrhagic Fevers (SAHF) from a clinical perspective that focuses on pathogenesis, clinical features, and diagnostics with an emphasis on therapies and vaccines that have demonstrated potential for use in an emergency situation through their evaluation in nonhuman primates (NHPs) and/or in humans.
METHODS: A standardized literature review was conducted on the clinical, pathological, vaccine, and treatment factors for SAHF as a group and for each individual virus/disease.
RESULTS: We identified 2 treatments and 1 vaccine platform that have demonstrated potential benefit for treating or preventing infection in humans and 4 other potential treatments currently under investigation.
CONCLUSION: We provide succinct summaries of these countermeasures to give the busy clinician a head start in reviewing the literature if faced with a patient with South American Hemorrhagic Fever. We also provide links to other authoritative sources of information.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Argentine hemorrhagic fever; Bolivian hemorrhagic fever; Brazilian hemorrhagic fever; Junín virus; Machupo virus; New World Arenavirus; South American hemorrhagic fevers; Venezuelan hemorrhagic fever

Year:  2021        PMID: 33610781     DOI: 10.1016/j.ijid.2021.02.046

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  2 in total

Review 1.  An updated review and current challenges of Guanarito virus infection, Venezuelan hemorrhagic fever.

Authors:  Carlos Ramiro Silva-Ramos; Carolina Montoya-Ruíz; Álvaro A Faccini-Martínez; Juan David Rodas
Journal:  Arch Virol       Date:  2022-05-17       Impact factor: 2.685

Review 2.  Commentary: Convalescent plasma to treat COVID-19: Following the Argentinian lead.

Authors:  Pierre Tiberghien; Eric Toussirot; Pascale Richard; Pascal Morel; Olivier Garraud
Journal:  Transfus Apher Sci       Date:  2021-05-23       Impact factor: 1.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.